





FAX Completed Form To 1.833.404.2392

Prescriber Help Desk 1.833.587.2012

Online

covermymeds.com/main/ prior-authorization-forms/

Request for Prior Authorization EXTENDED RELEASE FORMULATIONS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax	NDC
Payment for a non-preferred extended release formulation will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following conditions are met: 1) Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and 2) Previous trial and therapy failure with the preferred immediate release product of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance; and 3) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.		
Prior Authorization is required for the following extended release formulations: Adoxa, Amoxicillin ER, Astagraf XL, Augmentin XR, Cardura XL, Carvedilol ER, Coreg CR, Doryx, Elepsia XR, Envarsus XR, Glumetza, Gocovri, Gralise, Kapspargo, Keppra XR, Lamictal XR, Luvox CR, Memantine ER, Mirapex ER, Moxatag, Namenda XR, Oleptro, Osmolex ER, Oxtellar XR, pramipexole ER, pregabalin ER, Prozac Weekly, Qudexy XR, Rayos, Requip XL, Rythmol SR, Solodyn ER, topiramate ER, Trokendi XR, Ximino. Drug Name: Strength:		
Drug Name:	Strengun.	
Dosage Instructions:	Quantity: Days	s Supply:
Dosage Instructions:		s Supply:
Diagnosis:		ude strength, exact date ranges, and reason
Diagnosis: Previous therapy with immediate refor failure):	lease product of same chemical entity (inclu	ude strength, exact date ranges, and reason
Previous therapy with immediate refor failure): Previous therapy with a preferred defailure):	lease product of same chemical entity (inclu	rength, exact date ranges, and reason reason reason.
Previous therapy with immediate refor failure): Previous therapy with a preferred defailure):	lease product of same chemical entity (include strong of a different chemical entity (include strong of a different chemical entity (include strong of a preferred drug	rength, exact date ranges, and reason rength, exact date ranges, and reason for
Diagnosis: Previous therapy with immediate refor failure): Previous therapy with a preferred defailure): Contraindication(s) to using immed	lease product of same chemical entity (include strong of a different chemical entity (include strong of a preferred druge druge therapies:	rength, exact date ranges, and reason reason reason.

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.